Gain Therapeutics, Inc.
GANX
$1.71
-$0.04-2.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -100.00% |
| Cost of Revenue | -15.23% | 22.81% | 22.08% | 231.45% | 151.13% |
| Gross Profit | 15.23% | -22.81% | -22.57% | -234.88% | -153.10% |
| SG&A Expenses | -17.26% | -3.17% | -10.94% | -14.48% | -10.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.03% | -4.92% | -8.75% | -4.64% | -2.16% |
| Operating Income | 21.03% | 4.92% | 8.52% | 4.40% | 1.91% |
| Income Before Tax | 17.21% | 3.57% | 10.43% | 3.42% | 1.78% |
| Income Tax Expenses | 1,226.44% | 648.36% | 576.92% | -67.39% | -54.47% |
| Earnings from Continuing Operations | 13.92% | 1.03% | 8.34% | 3.83% | 2.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.92% | 1.03% | 8.34% | 3.83% | 2.08% |
| EBIT | 21.03% | 4.92% | 8.52% | 4.40% | 1.91% |
| EBITDA | 21.07% | 4.93% | 8.53% | 4.43% | 1.94% |
| EPS Basic | 50.90% | 42.04% | 45.18% | 37.73% | 27.07% |
| Normalized Basic EPS | 52.78% | 43.28% | 46.14% | 37.46% | 26.86% |
| EPS Diluted | 50.90% | 42.04% | 45.18% | 37.73% | 27.07% |
| Normalized Diluted EPS | 52.78% | 43.28% | 46.14% | 37.46% | 26.86% |
| Average Basic Shares Outstanding | 74.48% | 75.84% | 75.68% | 61.01% | 34.99% |
| Average Diluted Shares Outstanding | 74.48% | 75.84% | 75.68% | 61.01% | 34.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |